Skip to main content
SpringerLink
Log in
Book cover

Clinical Trial Registries pp 1–12Cite as

Clinical trial registries and publication of results — a primer

  • Chapter

  • 601 Accesses

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   39.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   54.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Simes RJ (1986) Publication bias: the case for an international registry of clinical trials. J Clin Oncol 4: 1529–1541

    PubMed  CAS  Google Scholar 

  2. Chalmers I (1990) Underreporting research is scientific misconduct. JAMA 263: 1405–1408

    Article  PubMed  CAS  Google Scholar 

  3. Davidoff F, DeAngelis CD, Drazen JM et al (2001) Sponsorship, authorship, and accountability. N Engl J Med 345: 825–826

    Article  PubMed  CAS  Google Scholar 

  4. Office of the New York State Attorney General Eliot Spitzer. Major pharmaceutical firm concealed information. Available at http://www.oag.state.ny.us/press/2004/jun/jun2b_04.html (Accessed 17 March 2005)

    Google Scholar 

  5. GlaxoSmithKline Clinical Trial register. Available at http;//ctr.gsk.co.uk/welcome.asp (Accessed 23 March 2005)

    Google Scholar 

  6. Merck. Merck announces voluntary worldwide withdrawal of VIOXX. September 30, 2004. Available at http://www.merck.co.vioxx_withdrawl/pdf/vioxx_press_release_final.pdf (Accessed 13 April 2006)

    Google Scholar 

  7. Gregory D, Curfman GD, Morrissey S, Drazen JM (2005) Expression of concern: Bombardier et al., “Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis” N Engl J Med 353: 2813–2814

    Article  Google Scholar 

  8. Bombardier C, Laine L, Reicin A et al (2000) Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. N Engl J Med 343: 1520–1528

    Article  PubMed  CAS  Google Scholar 

  9. Juni P, Nartey L, Reichenbach S, Sterchi R, Dieppe PA, Egger M (2004) Risk of cardiovascular events and rofecoxib: cumulative meta-analysis. Lancet 364: 2021–2029

    Article  PubMed  CAS  Google Scholar 

  10. Bombardier C, Laine L, Burgos-Vargas R et al (2006) Response to expression of concern regarding VIGOR study. N Engl J Med 354: 1196–1199

    Article  PubMed  CAS  Google Scholar 

  11. Silverstein FE, Faich G, Goldstein JL et al (2000) for the Celecoxib Long-Term Arthritis Safety Study. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: a randomized controlled trial. JAMA 284: 1247–1255

    Article  PubMed  CAS  Google Scholar 

  12. Solomon SD, McMurray JJ, Pfeffer MA et al (2005) Adenoma Prevention with Celecoxib (APC) Study Investigators. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med 352: 1071–1080

    Article  PubMed  CAS  Google Scholar 

  13. Hrackovec JB, Mora M. Reporting of 6-month vs 12-month data in a clinical trial of celecoxib. JAMA 386: 2398

    Google Scholar 

  14. Mukherjee D, Nissen SE, Topol EJ. Risk of cardiovascular events associated with selective COX-2 inhibitors. JAMA 286: 954–959

    Google Scholar 

  15. Pitt B, Pepine C, Willerson JT. Cyclooxygenase-2 inhibition and cardiovascular events. Circulation 106: 167–169

    Google Scholar 

  16. Mamdani M, Rochon P, Juurlink DN et al (2003) Effect of selective cyclooxygenase-2 inhibitors and naproxen on short-term risk of acute myocardial infarction in the elderly. Arch Intern Med 163: 481–486

    Article  PubMed  CAS  Google Scholar 

  17. Solomon DH, Schneesweiss S, Glynn RJ et al (2004) Relationship between selective cyclooxygenase-2 inhibitors and acute myocardial infarction in older adults. Circulation 109: 2068–2073

    Article  PubMed  CAS  Google Scholar 

  18. Graham DJ, Campen D, Hui R et al (2005) Risk of acute myocardial infarction and sudden cardiac death in patients treated with cyclooxygenase 2 selective and non-selective non-steroidal anti-inflammatory drugs: nested case-control study. Lancet 365: 475–481

    PubMed  CAS  Google Scholar 

  19. Eckert CH. Bioequivalence of levothyroxine preparations: industry sponsorship and academic freedom. JAMA 277: 1200–1201

    Google Scholar 

  20. Rennie D (1997) Thyroid storm. JAMA 277: 1238–1243

    Article  PubMed  CAS  Google Scholar 

  21. Spigelman MK. Bioequivalence of levothyroxine preparations for treatment of hypothyroidism. JAMA 277: 1199–1200

    Google Scholar 

  22. Weiss RB, Rifkin RM, Stewart FM et al (2000) High-dose chemotherapy for high-risk primary breast cancer: an on-site review of the Bezwoda study. Lancet 355: 999–1003

    Article  PubMed  CAS  Google Scholar 

  23. Weiss RB, Gill CG, Hudis CA (2001) An on-site audit of the South African trial of high-dose chemotherapy for metastatic breast cancer and associated publications. J Clin Oncol 19: 2771–2777

    PubMed  CAS  Google Scholar 

  24. European Commission. Enterprise an Industry Directorate-General. Guideline on the data fields from the European clinical trials database (EudraCT) that may be included in the European data base on Medicinal Products. Available at: http://pharmacos.eudra.org/F2/pharmacos/docs/Doc2005/03_05/Draft_guid_EudraCT_data_20050303.pdf (Accessed 17 March 2005)

    Google Scholar 

  25. United States Food and Drug Administration. Section 113 Food and Drug Administration Modernization Act of 1997. Available at: http://lhncbc.nlm.nih.gov/clin/113.html (Accessed 8 February 2006)

    Google Scholar 

  26. Fair Access to Clinical Trials Act of 2004, US Senate, S 2933, 108th Congress, Second Session. Available at: http://www.govtrack.us/data/us/bills.text/108/s2933.pdf (Accessed 9 February 2006)

    Google Scholar 

  27. Fair Access to Clinical Trials Act of 2004, House of Representatives, HR 5252, 108th Congress, Second Session. Available at: http://www.govtrack.us/data/us/bills.text/108/h5252.pdf (Accessed 9 February 2006)

    Google Scholar 

  28. Virginia. HB 2831/SB 1278. Publication of clinical trial results. Available at http://leg1.state.va.us/cgi-bin/legp504.exe?051+ful+CHAP0199 (Accessed 6 April 2006)

    Google Scholar 

  29. Maine. Governor’s Office of Health Policy and Finance. An Act Regarding Advertising by Drug Manufacturers and Disclosure of Clinical Trials. Available at http://www.maine.gov/dhhs (Accessed 5 April 2006)

    Google Scholar 

  30. De Angelis C, Drazen JM, Frizelle FA et al (2004) Clinical trial registration: a statement from the International Committee of Medical Journal Editors. JAMA 292: 1363–1364

    Article  Google Scholar 

  31. De Angelis C, Drazen JM, Frizelle FA, et al (2004) Is this clinical trial fully registered? A statement from the International Committee of Medical Journal Editors. JAMA 293: 2927–2929

    Article  Google Scholar 

  32. Abbasi K (2004) Compulsory registration of clinical trials. BMJ 329: 637–638

    Article  PubMed  Google Scholar 

  33. Pharmaceutical Research and Manufacturer’s Association. PhRMA adopts principles for conduct of clinical trials and communication of clinical trial results. Available at: http://www.phrma.org/mediaroom/press/releases/20.06.2002.427.cfm (Accessed 28 May 2003)

    Google Scholar 

  34. Pharmaceutical Research and Manufacturer’s Association. Pharmaceutical companies to make more information available about clinical trials. Available at http://www.phrma.org/mediaroom/press/releases/06.01.2005.1112.cfm (Accessed 13 March 2005)

    Google Scholar 

  35. Pharmaceutical Research and Manufacturer’s Association. International alliance of pharmaceutical associations agrees on principles for disclosing information Available at http://www.phrma.org/mediaroom/press/releases/06.01.2005.1114.cfm (Accessed 13 March 2005)

    Google Scholar 

  36. Bennett NL, Casebeer LL, Kristofeo RE, Strasser SM (2004) Physicians’ Internet information-seeking behaviors. J Conting Ed Health Profess 24: 31–38

    Article  Google Scholar 

  37. Lee J (2004) The power of negative thinking. Can J Emerg Med 6: 359–361

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Abraxis BioScience, Inc., 11777 San Vincente Blvd, Suite 550, Los Angeles, CA, 90049, USA

    MaryAnn Foote

Authors
  1. MaryAnn Foote
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Abraxis BioScience, Inc., 11777 San Vincente Blvd Suite 550, Los Angeles, CA, 90049, USA

    MaryAnn Foote

Rights and permissions

Reprints and permissions

Copyright information

© 2006 Birkhäuser Verlag Basel/Switzerland

About this chapter

Cite this chapter

Foote, M. (2006). Clinical trial registries and publication of results — a primer. In: Foote, M. (eds) Clinical Trial Registries. Birkhäuser Basel. https://doi.org/10.1007/978-3-7643-7583-6_1

Download citation

Publish with us

Policies and ethics

Search

Navigation